Insightful Word
  • Investing
  • Stock
  • Economy
  • Politics
  • Investing
  • Stock
  • Economy
  • Politics
No Result
View All Result
Insightful Word
No Result
View All Result
Home Stock

Biogen receives breakthrough therapy designation for felzartamab, shares edge up

admin by admin
October 9, 2024
in Stock
0
Biogen receives breakthrough therapy designation for felzartamab, shares edge up
0
SHARES
6
VIEWS
Share on FacebookShare on Twitter

Investing.com — Shares in Biogen (NASDAQ:BIIB) were trading marginally higher after the company said its investigational antibody felzartamab had received breakthrough therapy designation from US regulators as a treatment for late antibody-mediated rejection in kidney transplant patients.

In a statement on Tuesday, Massachusetts-based Biogen said the designation from the US Food and Drug Administration is given to drug candidates for serious or life-threatening conditions.

These medicine candidates have also shown preliminary evidence of providing substantial improvement over existing therapies, Biogen noted.

“Antibody-mediated rejection (AMR) is a major reason why kidney transplants fail, and currently patients suffering from AMR have tremendous unmet medical need,” said Travis Murdoch, Head of Biogen’s Human Immunology, or HI-Bio, unit.

“We are focused on tackling this important challenge, and the breakthrough therapy designation will enable us to work efficiently with the FDA to accelerate development of felzartamab in AMR.”

AMR is a disease where the immune system makes antibodies that damage transplanted organs.

Biogen said it plans to initiate late-stage trials for felzartamab across AMR and two other forms of kidney diseases in 2025. The treatment is still in an investigational phase, has not yet been approved by any regulatory authority, and its safety and effectiveness have not been established, Biogen flagged.

The announcements come after Biogen agreed to buy HI-Bio for up to $1.8 billion in May as part of a push to bolster its portfolio of rare disease medicines. The deal saw Biogen pay $1.15 billion in upfront costs and up to an additional $650 million if felzartamab hits certain development markers.

HI-Bio’s felzartamab has previously completed mid-stage studies for a type of kidney disease called primary membranous nephropathy, as well as AMR. The San Francisco-based group is also testing felzartamab in patients with IgA nephropathy, another version of chronic kidney disease.

(Reuters contributed reporting.)

This post appeared first on investing.com

Previous Post

Ethiopia sees bondholder losses as unavoidable, hopes for fresh talks at IMF meeting

Next Post

Consumers face high wheat prices as Russian supply shrinks, leaving limited options available

admin

admin

Next Post
Consumers face high wheat prices as Russian supply shrinks, leaving limited options available

Consumers face high wheat prices as Russian supply shrinks, leaving limited options available

Trending News

Panasonic to slash 10,000 jobs in 2025 amid Japan’s economic downturn

Panasonic to slash 10,000 jobs in 2025 amid Japan’s economic downturn

May 9, 2025
Top 4 catalysts for the S&P 500 VOO ETF stock this week

Top 4 catalysts for the S&P 500 VOO ETF stock this week

June 16, 2025
Online furniture retailer Wayfair to lay off 730 workers on its exit from Germany

Online furniture retailer Wayfair to lay off 730 workers on its exit from Germany

January 10, 2025
Subscribe to Insightful Word


    Recent News

    Goldman Sachs falls after HSBC downgrade on limited upside, caution on large banks

    Goldman Sachs falls after HSBC downgrade on limited upside, caution on large banks

    July 8, 2025
    Bank of America sees little upside for S&P 500 for rest of the year

    Bank of America sees little upside for S&P 500 for rest of the year

    July 8, 2025
    Datadog falls on Guggenheim downgrade despite upcoming S&P 500 debut: read why

    Datadog falls on Guggenheim downgrade despite upcoming S&P 500 debut: read why

    July 8, 2025
    US stocks jittery as tariff concerns remain: S&P flat, Dow slips at open

    US stocks jittery as tariff concerns remain: S&P flat, Dow slips at open

    July 8, 2025

    Recent News

    Goldman Sachs falls after HSBC downgrade on limited upside, caution on large banks

    Goldman Sachs falls after HSBC downgrade on limited upside, caution on large banks

    July 8, 2025
    Bank of America sees little upside for S&P 500 for rest of the year

    Bank of America sees little upside for S&P 500 for rest of the year

    July 8, 2025

    Latest News

    • Goldman Sachs falls after HSBC downgrade on limited upside, caution on large banks
    • Bank of America sees little upside for S&P 500 for rest of the year
    • Datadog falls on Guggenheim downgrade despite upcoming S&P 500 debut: read why

    About Insightful Word

    • Contacts
    • Cookie Notice
    • Privacy Policy
    • Terms of Service
    • Trading tools
    • Contacts
    • Cookie Notice
    • Privacy Policy
    • Terms of Service
    • Trading tools

    Copyright © 2025 Insightfulword.com. All Rights Reserved.

    No Result
    View All Result
    • Investing
    • Stock
    • Economy
    • Politics

    Copyright © 2025 Insightfulword.com. All Rights Reserved.